Breaking News Instant updates and real-time market news.

SNY

Sanofi

$46.42

0.17 (0.37%)

10:36
09/30/19
09/30
10:36
09/30/19
10:36

Sanofi reports CARD study results presented at ESMO, published in NEJM

Data published in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer, mCRPC, previously treated with docetaxel and who progressed within 12 months on an androgen receptor-targeted agent experienced significantly longer radiographic progression free survival, or rPFS, with Jevtana plus prednisone compared with abiraterone plus prednisone or enzalutamide, Sanofi announced. Overall survival with Jevtana was also significantly longer, the company said. These findings from the CARD study were presented today in the Presidential Symposium of the 2019 European Society of Medical Oncology Congress, or ESMO. The study's primary endpoint was rPFS, which more than doubled with Jevtana treatment compared to abiraterone or enzalutamide. Patients treated with Jevtana experienced an improvement in rPFS in all pre-specified subgroups, irrespective of the timing of the previous alternative AR-targeted agent, before or after docetaxel. Jevtana also significantly improved a key secondary endpoint, OS, reducing the risk of death from any cause by 36% compared with abiraterone or enzalutamide. Other key secondary endpoints all favored Jevtana, the company said.

  • 02

    Oct

SNY Sanofi
$46.42

0.17 (0.37%)

09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy from Neutral at Guggenheim
09/20/19
MSCO
09/20/19
UPGRADE
MSCO
Overweight
Morgan Stanley upgrades 'defensive' Sanofi to Overweight
As previously reported, Morgan Stanley upgraded Sanofi to Overweight from Equal Weight with analyst Mark Purcell arguing that the company has the lowest risk growth outlook in European pharma given its lack of major patent cliffs and the "largely de-risked" nature of pipeline drugs in the late stages. He thinks Sanofi's defensive qualities position it as a key holding in the current environment and also believes the company's new CEO Paul Hudson has significant optionality to unlock shareholder value, Purcell tells investors. He raised his price target on Sanofi shares to EUR90 from EUR79.

TODAY'S FREE FLY STORIES

BRMK

Broadmark Realty Capital

$10.94

-0.02 (-0.18%)

07:40
11/22/19
11/22
07:40
11/22/19
07:40
Initiation
Broadmark Realty Capital initiated  »

Broadmark Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/22/19
11/22
07:40
11/22/19
07:40
General news
Treasury Market Outlook: bond yields are modestly richer outside of Asia »

Treasury Market Outlook:…

NKSH

National Bankshares

$47.08

1.59 (3.50%)

07:39
11/22/19
11/22
07:39
11/22/19
07:39
Downgrade
National Bankshares rating change  »

National Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$2.03

0.01 (0.50%)

07:37
11/22/19
11/22
07:37
11/22/19
07:37
Initiation
Precipio initiated  »

Precipio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$288.66

3.68 (1.29%)

07:36
11/22/19
11/22
07:36
11/22/19
07:36
Hot Stocks
Biogen announces results from Phase 3 EVOLVE-MS-2 study »

Biogen announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

APDN

Applied DNA Sciences

$4.14

(0.00%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Upgrade
Applied DNA Sciences rating change  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$126.80

-0.04 (-0.03%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

LYFT

Lyft

$46.77

2.92 (6.66%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

ZM

Zoom Video

$69.91

-1.02 (-1.44%)

07:34
11/22/19
11/22
07:34
11/22/19
07:34
Initiation
Zoom Video initiated  »

Guggenheim starts Zoom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:33
11/22/19
11/22
07:33
11/22/19
07:33
Hot Stocks
Auxly says company 'ready to enter' Cannabis 2.0 market on first day of sales »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

, F

Ford

$8.72

-0.005 (-0.06%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Recommendations
Tesla, Ford, General Motors analyst commentary  »

Tesla's $39,900…

TSLA

Tesla

F

Ford

$8.72

-0.005 (-0.06%)

GM

General Motors

$34.66

-0.6 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 09

    Dec

  • 04

    Feb

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMSY

HMS Holdings

$29.51

0.52 (1.79%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Upgrade
HMS Holdings rating change  »

Guggenheim upgrades HMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:31
11/22/19
11/22
07:31
11/22/19
07:31
Earnings
Auxly Cannabis reports Q3 EPS (C$0.03) vs. (C$0.02) last year »

Reports Q3 revenue C$1.6M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$85.30

-0.41 (-0.48%)

07:30
11/22/19
11/22
07:30
11/22/19
07:30
Hot Stocks
Anixter, CD&R announce amendment to up merger consideration to $82.50 per share »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:28
11/22/19
11/22
07:28
11/22/19
07:28
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$52.46

-1.9 (-3.50%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Recommendations
Emergent BioSolutions analyst commentary  »

Cantor reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$47.17

1.2 (2.61%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Periodicals
Sanofi EVP in charge of strategy leaving by end of month, Reuters says »

Muzammil Mansuri,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NXRT

NexPoint Residential

$47.61

-0.49 (-1.02%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Initiation
NexPoint Residential initiated  »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$28.49

-0.15 (-0.52%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Initiation
Apellis initiated  »

Apellis has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KKR

KKR

$29.07

-0.25 (-0.85%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Periodicals
KKR gets halfway in $3B Asia infrastructure fundraising, Reuters says »

According to Reuters, KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.70

-0.21 (-3.55%)

07:25
11/22/19
11/22
07:25
11/22/19
07:25
Conference/Events
RedHill Biopharma to host investor & analyst day »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

BXRX

Baudax Bio

$4.66

-0.59 (-11.24%)

07:24
11/22/19
11/22
07:24
11/22/19
07:24
Initiation
Baudax Bio initiated  »

Baudax Bio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.89

1.41 (2.69%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Biohaven Pharmaceutical initiated  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$56.84

0.455 (0.81%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Bristol-Myers initiated  »

Bristol-Myers resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.